NASDAQ:BMRN
Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc.'s revenue grew 12.9% in fiscal 2025 to $3.2B while operating margin fell to 12.7%. Free cash flow was $725.0M, 22.5% of revenue.Summary generated from Biomarin Pharmaceutical Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.2B
Revenue growth+12.9%
Revenue, 5-yr CAGR+11.6%
Gross margin77.7%
Operating margin12.7%
Net margin10.8%
ROICn/a
Return on equity5.9%
Debt / equityn/a
Free cash flow$725.0M
FCF margin22.5%
Share count change+0.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,846 | 2,096 | 2,419 | 2,854 | 3,221 |
| Operating income | −82 | 161 | 186 | 484 | 409 |
| Net income | −64 | 142 | 168 | 427 | 349 |
| Free cash flow | 209 | 55 | 63 | 487 | 725 |
Recent filings
- 8-KResults of operations and financial condition
Oct 6, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KEntry into a material agreement
Sep 30, 2026 - 8-KOther events
Sep 15, 2026 - 4Insider transaction report
Sep 14, 2026 - 8-KDirector or officer change
Sep 14, 2026 - 8-KOther events
Sep 1, 2026 - 8-KEntry into a material agreement
Aug 31, 2026